Integra LifeSciences Holdings Corporation

Integra LifeSciences Holdings Corporation

IARTยทNASDAQ

$16.10

+2.7%
HealthcareMedical - Devices

Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, and general surgery. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as asset management software and support, and after-market services. It also sells approximately 40,000 instrument patterns, and surgical and lighting products to hospitals and surgery centers, as well as dental, podiatry, and veterinary offices. In addition, the company provides regenerative technology products for the treatment of acute and chronic wounds; and surgical tissue repair products for hernia repair, peripheral nerve repair and protection, and tendon repair. Further, it offers skin and wound repair, plastics and surgical reconstruction products, bone grafts, and nerve and tendon repair products. The company offers its products directly through various sales forces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, Asia Pacific, and internationally. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey.

At a Glance

Live Snapshot
Market Cap$1.25B
EPS-6.7300
P/E Ratio-2.39
Earnings Date07/30/2026
Integra LifeSciences Holdings Corporation

Integra LifeSciences Holdings Corporation Fair Value Envelope

IART ยท NASDAQ

Our analysis suggests that IART has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $16.1, this represents a potential HIDDEN relative to our calculated worth for Integra LifeSciences Holdings Corporation.

Intrinsic Value
Current Price: $16.1

Owner Earnings Valuation Tool

Warren Buffett's Owner Earnings DCF analysis for intrinsic value calculation

Historical Financial Data

Base year metrics used for projections

$
%
$
%
$
$

Projection Settings

Forecast period and terminal assumptions

%
%

DCF Valuation Summary

Calculation flow from present value to intrinsic value per share

Present Value$29.6M
+ Cash & Equivalents$235.0M
Firm Value$264.7M
- Debt$2.0B
Equity Value-$1.8B
/ Shares Outstanding77,892,111B
DCF Value-$23
OVERVALUED BY 241%

Owner Earnings Projections

Operating Cash Flow - Maintenance CapEx = Owner Earnings

Metric
Year 1
Year 2
Year 3
Year 4
Year 5
Year 6
Year 7
Year 8
Year 9
Year 10
Operating Cash Flow
$25.2M
$12.6M
$6.3M
$3.1M
$1.6M
$787.3K
$393.6K
$196.8K
$98.4K
$49.2K
Maintenance CapEx
-$8.1M
-$4.1M
-$2.0M
-$1.0M
-$509.0K
-$254.5K
-$127.2K
-$63.6K
-$31.8K
-$15.9K
Owner Earnings
$17.0M
$8.5M
$4.3M
$2.1M
$1.1M
$532.8K
$266.4K
$133.2K
$66.6K
$33.3K
Discount Factor
0.926
0.857
0.794
0.735
0.681
0.630
0.583
0.540
0.500
0.463
Present Value
$15.8M
$7.3M
$3.4M
$1.6M
$725.2K
$335.7K
$155.4K
$72.0K
$33.3K
$15.4K
Terminal Value represents 0.9% of Enterprise Value